Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Annals of Surgical Oncology

Volumn 20, Issue 12, 2013, Pages 3823-3830

  Mukhtar, Rita A ^a   Yau, Christina ^a   Rosen, Mark ^b   Tandon, Vickram J ^a   Hylton, Nola ^a   Esserman, Laura J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS;

EID: 84886093788     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3038-y     Document Type: Article

References (45)

1. Esserman LJ, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012;132:1049-62.
2. Esserman LJ, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30:3242-9.
3. Fisher B, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672-85.
4. Wolmark N, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
5. Rastogi P, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778-85.
6. Hortobagyi GN, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983;51(5):763-8.
7. Shenoy HG, et al. Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer. Surg Oncol. 2009;18(1):65-71.
8. Caldon LJ, Walters SJ, Reed MW. Changing trends in the decision-making preferences of women with early breast cancer. Br J Surg. 2008;95(3):312-8.
9. Chen JH, et al. Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer. Ann Surg. 2009;249(3):448-54.
10. Morrow M. Magnetic resonance imaging for screening, diagnosis, and eligibility for breast-conserving surgery: promises and pitfalls. Surg Oncol Clin N Am. 2010;19(3):475-92.
11. Morrow M. Magnetic resonance imaging in the preoperative evaluation of breast cancer: primum non nocere. J Am Coll Surg. 2004;198(2):240-1.
12. Houssami N, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol. 2008;26(19):3248-58.
13. Kwong MS, et al. Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer J. 2006;12(3):212-21.
14. Chagpar AB, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006;243(2):257-64.
15. Bhattacharyya M, et al. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2008;98(2):289-93.
16. McLaughlin R, Hylton N. MRI in breast cancer therapy monitoring. NMR Biomed. 2011;24(6):712-20.
17. Lorenzon M, et al. Assessment of breast cancer response to neoadjuvant chemotherapy: is volumetric MRI a reliable tool? Eur J Radiol. 2009;71(1):82-8.
18. Stucky CC, et al. Does magnetic resonance imaging accurately predict residual disease in breast cancer? Am J Surg. 2009;198(4):547-52.
19. Lee JM, et al. MRI before reexcision surgery in patients with breast cancer. AJR Am J Roentgenol. 2004;182(2):473-80.
20. Esserman L, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001;8(6):549-59.
21. Hylton NM, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012;263(3):663-672.
22. Symmans WF, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-22.
23. Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-41.
24. Kruskal WH, Wallis WA. Citation classic: use of ranks in one-criterion variance analysis. Curr Contents Arts Humanit. 1987(40):20.
25. Pearson K. On the theory of contingency and its relation to association and normal correlation. London: Dulau and Co.; 1904. p 35.
26. Gomez R, et al. Preliminary results from I-SPY trial: tumor patterns on pre-treatment MRI predict breast conservation therapy eligibility. In: San Antonio Breast Cancer Symposium 2007: San Antonio, TX.
27. McGuire KP, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol. 2011;18(11):3149-54.
28. Livasy CA, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264-71.
29. Fulford LG, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22-34.
30. Chen JH, et al. Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol. 2007;18(12):2042-3.
31. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology. 2009;250(3):638-47.
32. Wang Y, et al. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology. 2008;246(2):367-75.
33. Wang X, et al. The mammographic correlations with basal-like phenotype of invasive breast cancer. Acad Radiol. 2010;17(3):333-9.
34. Chen JH, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112(1):17-26.
35. Straver ME, et al. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg. 2010;251(4):701-7.
36. Loo CE, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol. 2011;29(6):660-6.
37. Nakahara H, et al. MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes. Breast Cancer. 2010;18(3):152-60.
38. Moon HG, et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol. 2009;20(4):636-41.
39. Esserman LJ, et al. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol. 2006;24(28):4603-10.
40. Kumar AS, et al. Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. Am J Surg. 2006;192(4):520-4.
41. Mamounas EP. NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology (Williston Park). 1997;11(6 Suppl 6):37-40.
42. Fangberget A, et al. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol. 2011;21(6):1188-99.
43. Wasser K, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol. 2003;13(6):1213-23.
44. Alvarado M, et al. Predictors of local recurrence in high-risk patients undergoing neoadjuvant chemotherapy in the ISPY trial. In: San Antonio Breast Cancer Symposium. 2010. San Antonio, TX.
45. Kim HJ, et al. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncol. 2007;46(7):996-1003.